Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Nature Medicine2015Vol. 21(6), pp. 560–562
Citations Over TimeTop 1% of 2015 papers
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard
Related Papers
- → Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy(2017)106 cited
- → Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation(2020)25 cited
- → EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors(2018)20 cited
- → P2.03-040 EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients(2017)1 cited
- → Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.(2019)1 cited